BiomX Inc. (PHGE) - Dilution Analysis

10-Q filing | 10.1M shares outstanding

8-K filing: BiomX Inc. purchased 60% of the issued and outstanding voting equity capital of DR. Frucht Systems Ltd. by paying $750,000 in cash, issuing a $3,000,000 convertible promissory note, issuing 923,000 shares of common stock, issuing pre-funded warrants exercisable for 923,000 shares of common stock, and issuing a five-year warrant exercisable for 3,692,000 shares of common stock.

8-K filing: BiomX Inc. amended a warrant with an investor to reduce the exercise price from $2.00 to $1.00 per share and revise the method of determining the number of shares issuable upon a cashless exercise.

8-K filing: On January 13, 2026, the Company issued 3,300 shares of Series Y Convertible Preferred Stock in a private placement.

8-K filing: BiomX Inc. entered into a Securities Purchase Agreement to issue and sell Series Y Convertible Preferred Stock and warrants for expected gross proceeds of $3.0 million. ($3.0M proceeds)

8-K filing: Stock split 1-for-19 | Outstanding: 31,399,552 → 1,652,558

10-Q filing | 31.4M shares outstanding

10-Q filing | 26.5M shares outstanding

10-Q filing | 26.2M shares outstanding

S-1 filing: This S-1 filing registers the resale of common stock issuable upon the exercise of pre-funded warrants, common warrants, and new warrants by selling securityholders.

10-K filing | 25.0M shares outstanding

8-K filing: BiomX Inc. entered into a securities purchase agreement for a registered direct offering and concurrent private placement, involving the issuance of common stock, pre-funded warrants, and common warrants, and also entered into inducement letter agreements with holders of existing warrants to exercise them at a reduced price in exchange for new warrants, with the gross proceeds from the registered direct offering, private placement, and warrant exercises expected to be approximately $12 million. ($9.1M proceeds)

10-Q filing | 16.4M shares outstanding

8-K filing: Stock split one-for-ten (1:10) | Outstanding: 178,958,447 → 17,895,844

10-Q filing | 179.0M shares outstanding

S-3/A filing: This prospectus relates to the resale by the selling securityholders named in this prospectus of (i) up to 40 Warrants to purchase up to 120,148,806 shares of Common Stock, (ii) up to 147,735 shares of our series X non-voting convertible preferred stock and (iii) up to 386,200,774 shares of common stock.

S-3/A filing: This prospectus relates to the resale by the selling securityholders of (i) warrants to purchase up to 120,148,806 shares of Common Stock, (ii) up to 147,735 shares of series X non-voting convertible preferred stock and (iii) up to 386,200,774 shares of common stock.

10-Q filing | 69.8M shares outstanding

S-3 filing: This prospectus relates to the resale by the selling securityholders named in this prospectus or their permitted transferees of (i) Warrants to purchase up to 120,148,806 shares of Common Stock, (ii) up to 256,887 shares of Series X Preferred Stock and (iii) up to 386,200,774 shares of common stock.

10-K filing | 51.3M shares outstanding

8-K filing: BiomX Inc. entered into a merger agreement with Adaptive Phage Therapeutics, Inc. and a Securities Purchase Agreement for a private placement of Series X Preferred Stock and warrants, contingent upon the merger. ($100.0M proceeds)

S-3/A filing: The company is filing an S-3/A to register the offering of common stock, preferred stock, and debt securities, with an aggregate initial offering price of $150,000,000.

S-3 filing: The company is filing an S-3 form to register the offering of common stock, preferred stock, and debt securities for an aggregate initial offering price of $150,000,000, as well as an ATM offering of common stock through Wainwright.

10-Q filing | 46.0M shares outstanding

10-Q filing | 46.0M shares outstanding

S-3 filing: This S-3 filing registers 31,775,477 shares of common stock for resale by selling stockholders.

10-Q filing | 46.0M shares outstanding

8-K filing: BiomX Inc. completed the second closing of a private placement on May 4, 2023, issuing 24,632,243 shares of common stock and pre-funded warrants for gross proceeds of approximately $6.0 million. ($6.0M proceeds)

10-K filing | 33.2M shares outstanding

8-K filing: BiomX Inc. completed the first closing of a private placement offering on February 27, 2023, issuing 5,975,919 shares and pre-funded warrants for gross proceeds of approximately $1.5 million. ($1.5M proceeds)

8-K filing: BiomX Inc. executed a definitive Securities Purchase Agreement for a private placement of 30,608,163 shares of common stock at $0.245 per share, with an initial closing of 5,975,918 shares and a second closing contingent upon stockholder approval, anticipating gross proceeds of approximately $7.5 million. ($3.0M proceeds)

10-Q filing | 30.0M shares outstanding

10-Q filing | 30.0M shares outstanding

10-Q filing | 29.8M shares outstanding

10-K filing | 29.8M shares outstanding

S-3 filing: This prospectus relates to the resale by the selling stockholder named in this prospectus or its permitted transferees of up to 375,000 shares of our common stock, par value $0.0001 per share.

10-Q filing | 28.6M shares outstanding

10-Q filing | 28.2M shares outstanding

8-K filing: BiomX Inc. entered into a securities purchase agreement to issue and sell 3,750,000 units, each consisting of one share of common stock and one warrant to purchase 0.75 of a share of common stock, at $4.00 per unit, for gross proceeds of $15.0 million. ($15.0M proceeds)

10-Q filing | 24.3M shares outstanding

10-K filing | 22.9M shares outstanding

S-3 filing: The company is filing an S-3 to register the offering of common stock, preferred stock, debt securities, warrants to purchase common stock, and units of two or more of such securities, in one or more offerings for an aggregate initial offering price of $150,000,000.

POS AM filing: This prospectus relates to the resale by the selling security holders of up to 22,023,881 shares of common stock and 2,900,000 warrants to purchase common stock.

10-Q filing | 22.9M shares outstanding

10-Q filing | 22.9M shares outstanding

10-Q filing | 22.9M shares outstanding

10-K filing | 22.9M shares outstanding